Central retinal vein occlusion and pseudoexfoliation syndrome

Figures & data

Table 1 Patient demographics and comparisons between groups

	CRVO	BRVO	Control group	P-value
n (%)	48	164	70
Age, years (mean[SD])	67 (SD 14.26, range 33–90)	70 (SD 9.15, range 39–93)	67 (SD 10.64, range 40–89)	0.105 (ANOVA)
Systemic hypertension	25 (52%)	94 (57%)	42 (60%)	0.69 (chi-square test)
Hyperlipidemia	13 (27%)	38 (23%)	17 (24%)	0.85 (chi-square test)
Diabetes mellitus	5 (10%)	33 (20%)	15 (21%)	0.25 (chi-square test)
PXF	14 (29%)	14 (8.5%)	6 (8.6%)	<0.001 (chi-square test)

Note: Statistically significant P-values are in bold font.

Abbreviations: n, number of patients; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; SD, standard deviation; ANOVA, analysis of variance; PXF, pseudoexfoliation syndrome.

Figure 1 Histogram representing the percentage of PXF among each of the groups in the study.

Abbreviations: PXF, pseudoexfoliation syndrome; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion.

Table 2 Comparison between ischemic and non-ischemic CRVO

	Ischemic CRVO	Non-ischemic CRVO	P-value
n	27	21
Age, years (mean[SD])	69 (SD 13.12)	63 (SD 15.31)	0.174 (t-test)
PXF	13	1
PXF%	48%	4.76%	0.001 (chi-square test)

Abbreviations: n, number of patients; PXF, pseudoexfoliation syndrome; CRVO, central retinal vein occlusion; SD, standard deviation.

Figure 2 Histogram representing the percentage of PXF in the two subgroups of ischemic central retinal vein occlusion (CRVO) and non-ischemic CRVO.

Abbreviation: PXF, pseudoexfoliation syndrome.